toprisan 50mg film coated tablets
medochemie ltd (0000003169) 1-10 constantinoupoleos str, lemesos, 3011, 51409 (3505) - itopride hydrochloride - film coated tablets - 50mg - itopride hydrochloride (0122898673) 50mg - itopride
progit® f.c.tab 50mg/tab
kappler pharma consult gmbh, germany fonyoder strasse 18,, 89340, leipheim, +49(0) 8221 916033 0 - itopride hydrochloride - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - 50mg/tab - itopride hydrochloride 50mg - itopride
pridaton 50mg film coated tablets
codal-synto limited (0000010484) 21 constantinoupoleos str., limassol, 3011, 51785 (3508) - itopride hydrochloride - film coated tablets - 50mg - itopride hydrochloride (0122898673) 50mg
istopril 5mg tablets
codal-synto limited (0000010484) 21 constantinoupoleos str., limassol, 3011, 51785 (3508) - enalapril maleate - tablets - 5mg - enalapril maleate (0076095164) 5mg - enalapril
istopril 10mg tablets
codal-synto limited (0000010484) 21 constantinoupoleos str., limassol, 3011, 51785 (3508) - enalapril maleate - tablets - 10mg - enalapril maleate (0076095164) 10mg - enalapril
istopril 20mg tablets
codal-synto limited (0000010484) 21 constantinoupoleos str., limassol, 3011, 51785 (3508) - enalapril maleate - tablets - 20mg - enalapril maleate (0076095164) 20mg - enalapril
dexatopic cream
organon s.a. france - dexamethasone - ΚΡΕΜΑ - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ
dexatopic ointment
organon s.a. france - dexamethasone - ΑΛΟΙΦΗ - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ
dupixent
sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - Παράγοντες για δερματίτιδα, εξαιρουμένων των κορτικοστεροειδών - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.
rasilez
noden pharma dac - αλισκιρένη - Υπέρταση - Παράγοντες που δρουν στο σύστημα ρενίνης-αγγειοτενσίνης - Θεραπεία της ιδιοπαθούς υπέρτασης.